Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

44.16 -1.02 (-2.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 822,244
Open 45.56
Bid (Size) 44.16 (1)
Ask (Size) 44.32 (2)
Prev. Close 45.18
Today's Range 44.01 - 45.70
52wk Range 38.94 - 86.95
Shares Outstanding 78,646,679
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best Growth Stocks to Buy in the Biotech Sector
These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors. 
Via InvestorPlace
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace

Performance

YTD
+7.71%
+7.71%
1 Month
-10.46%
-10.46%
3 Month
+9.50%
+9.50%
6 Month
-31.52%
-31.52%
1 Year
-31.09%
-31.09%

More News

Read More
Why Bluebird Bio Shares Are Plunging Today
Via Benzinga
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could This Stock Become the Tesla of Its Industry?
Via The Motley Fool
Expert Ratings for CRISPR Therapeutics
Via Benzinga
Could CRISPR Therapeutics Become the Next Moderna?
Via The Motley Fool
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Via InvestorPlace
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence
Via The Motley Fool
This Cathie Wood Stock Could Nearly Double, According to Wall Street
Via The Motley Fool
Thinking of Buying Biotech Stocks? Do These 3 Things First
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time
Via InvestorPlace
3 Beaten-Down Stocks That Could Soar This Year
Via The Motley Fool
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
If You Invested $10,000 in CRISPR Therapeutics In 2020, This Is How Much You Would Have Today
Via The Motley Fool
Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold
Via The Motley Fool
2 Healthcare Stocks That Could Help Make You a Fortune
Via The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
Via InvestorPlace
Better Growth Stock: Moderna vs. CRISPR Therapeutics
Via The Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
Via The Motley Fool
3 Game-Changing Stocks to Buy in March
Via The Motley Fool
2 Soaring Stocks to Buy and Hold Through 2023 and Beyond
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.